Karydas Daphne
Mineralys Therapeutics, Inc. · Director
Karydas Daphne is listed in filings as Director at Mineralys Therapeutics, Inc.. This profile follows SEC Form 4 activity through Jun 17, 2026, including sale activity. Recent filings connect the profile to Mineralys Therapeutics, Inc. (MLYS) and COMPASS Pathways plc (CMPS). The current snapshot covers public activity from Feb 24, 2025 to Jun 17, 2026. Reported amounts are shown as $75.0K to $335.6K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.
History Trades
| Company | Value | Action | Price | Last Price |
|---|---|---|---|---|
| $226k4.9k shares | SellNov 13, 2025 | $46.36 | $26.71 | |
| $463k10.1k shares | SellNov 13, 2025 | $45.81 | $26.71 | |
| $75k3k shares | SellMar 31, 2026 | $25.00 | $26.71 |